| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $2,359,971 ) |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 19 | NIH | 8/7/2025 | $180,901 |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 004 | 19 | NIH | 9/24/2025 | $81,861 |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 003 | 19 | NIH | 8/8/2025 | $11,513 |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 003 | 19 | NIH | 8/8/2025 | $142,830 |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UG1CA284671 | CAPRISA CASCADE Clinical Trials Network Clinical Research Site | 000 | 3 | NIH | 9/5/2025 | $216,000 |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 19 | NIH | 8/7/2025 | $708,687 |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 19 | NIH | 11/11/2024 | $192,415 |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 19 | NIH | 11/11/2024 | $851,518 |
| | 2025 | 2025 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI162001 | Mechanisms of type I IFN signaling and HIV risk in the female genital tract | 000 | 5 | NIH | 7/25/2025 | $98,964 |
| | 2025 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 5 | NIH | 8/8/2025 | $0 |
| | 2025 | 2020 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 000 | 14 | NIH | 10/1/2024 | -$124,718 |
|
| Issue Date FY: 2024 ( Subtotal = $3,637,643 ) |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 5 | NIH | 3/27/2024 | $143,548 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UG1CA284671 | CAPRISA CASCADE Clinical Trials Network Clinical Research Site | 002 | 2 | NIH | 9/12/2024 | $125,000 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UG1CA284671 | CAPRISA CASCADE Clinical Trials Network Clinical Research Site | 001 | 2 | NIH | 6/13/2024 | $216,000 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 18 | NIH | 5/31/2024 | $110,564 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 18 | NIH | 5/31/2024 | $740,450 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 000 | 18 | NIH | 11/2/2023 | $110,564 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI162001 | Mechanisms of type I IFN signaling and HIV risk in the female genital tract | 000 | 4 | NIH | 3/18/2024 | $122,682 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 000 | 4 | NIH | 3/19/2024 | $282,070 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 003 | 5 | NIH | 7/31/2024 | $285,787 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 002 | 5 | NIH | 7/30/2024 | $200,932 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 001 | 5 | NIH | 7/25/2024 | $290,914 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UG1CA284671 | CAPRISA CASCADE Clinical Trials Network Clinical Research Site | 003 | 2 | NIH | 9/20/2024 | $0 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 18 | NIH | 6/4/2024 | $133,771 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 000 | 18 | NIH | 11/2/2023 | $740,450 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 001 | 5 | NIH | 5/7/2024 | $15,950 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 001 | 5 | NIH | 5/7/2024 | $9,111 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 002 | 5 | NIH | 6/5/2024 | $2,785 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 5 | NIH | 3/27/2024 | $107,065 |
| | 2024 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UG1CA284671 | CAPRISA CASCADE Clinical Trials Network Clinical Research Site | 000 | 1 | NIH | 10/16/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,673,620 ) (Continued on the next page) |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 4 | NIH | 3/15/2023 | $141,990 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 003 | 17 | NIH | 5/19/2023 | $110,186 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 003 | 17 | NIH | 5/19/2023 | $151,057 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 003 | 17 | NIH | 5/19/2023 | $866,529 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 17 | NIH | 2/7/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 17 | NIH | 2/7/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 17 | NIH | 11/21/2022 | $110,186 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 17 | NIH | 11/21/2022 | $866,529 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 004 | 17 | NIH | 5/31/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 004 | 17 | NIH | 5/31/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | K43TW011437 | Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa | 000 | 5 | NIH | 4/11/2023 | $112,056 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 002 | 4 | NIH | 8/4/2023 | $369,940 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 001 | 4 | NIH | 8/3/2023 | $303,515 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UG1CA284671 | CAPRISA CASCADE Clinical Trials Network Clinical Research Site | 000 | 1 | NIH | 9/5/2023 | $216,000 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 004 | 17 | NIH | 5/31/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI162001 | Mechanisms of type I IFN signaling and HIV risk in the female genital tract | 000 | 3 | NIH | 3/2/2023 | $124,785 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 4 | NIH | 3/15/2023 | $170,999 |
|
